Soligenix (NASDAQ: SNGX) Interview with Christopher Schaber, PhD CEO and President
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization […]